Biomarker discovery for renal cancer stem cells.
Biomarker discovery for renal cancer stem cells.
复制标题
肾癌干细胞的生物标志物发现。
DOI：
10.1002/cjp2.91
复制
发表时间：
2018-01
期刊：
影响因子：
--
通讯作者：
Moch H
中科院分区：
文献类型：
--
作者：
Corrò C;Moch H
转移性肾细胞癌（RCC）具有肿瘤内和肿瘤间的高度异质性，对化疗和放疗具有耐药性。因此，需要为RCC患者开发新的预后和诊断标志物。肿瘤干细胞（CSCs）是肿瘤内的一小群肿瘤细胞，具有与正常干细胞相似的特征。CSCs的特点是无限制的细胞分裂，维持干细胞库（自我更新），并能够在肿瘤内产生所有类型的细胞；并有助于体内转移（致瘤性），治疗抵抗和复发。迄今为止，许多研究都试图建立独特的生物标志物来识别RCC中的CSC群体。与此同时，为了分离csc，已经开发了不同的方法。因此，我们发现了一些标志物在csc和来自RCC的癌症干细胞样细胞中特异性表达，如CD105、ALDH1、OCT4、CD133和CXCR4。然而，遗传和表观遗传机制以及肿瘤微环境对细胞可塑性的贡献使得发现独特的生物标志物变得非常困难。事实上，文献中已经报道了关于这些标记物在分离肾csc方面的适用性的对比结果。因此，更好地了解CSC的机制可能有助于剖析肿瘤的异质性和药物治疗效率。
Characterised by high intra‐ and inter‐tumor heterogeneity, metastatic renal cell carcinoma (RCC) is resistant to chemo‐ and radiotherapy. Therefore, the development of new prognostic and diagnostic markers for RCC patients is needed. Cancer stem cells (CSCs) are a small population of neoplastic cells within a tumor which present characteristics reminiscent of normal stem cells. CSCs are characterised by unlimited cell division, maintenance of the stem cell pool (self‐renewal), and capability to give rise to all cell types within a tumor; and contribute to metastasis in vivo (tumourigenicity), treatment resistance and recurrence. So far, many studies have tried to establish unique biomarkers to identify CSC populations in RCC. At the same time, different approaches have been developed with the aim to isolate CSCs. Consequently, several markers were found to be specifically expressed in CSCs and cancer stem‐like cells derived from RCC such as CD105, ALDH1, OCT4, CD133, and CXCR4. However, the contribution of genetic and epigenetic mechanisms, and tumor microenvironment, to cellular plasticity have made the discovery of unique biomarkers a very difficult task. In fact, contrasting results regarding the applicability of such markers to the isolation of renal CSCs have been reported in the literature. Therefore, a better understanding of the mechanism underlying CSC may help dissecting tumor heterogeneity and drug treatment efficiency.
登录
查看更多内容
影响因子：
3.2
作者：
Abourbih S;Sircar K;Tanguay S;Kassouf W;Aprikian A;Mansure J;Brimo F
通讯作者：
Brimo F
影响因子：
5.2
作者：
Angelotti, Maria Lucia;Ronconi, Elisa;Romagnani, Paola
通讯作者：
Romagnani, Paola
影响因子：
4.8
作者：
Bussolati, Benedetta;Bruno, Stefania;Camussi, Giovanni
通讯作者：
Camussi, Giovanni
影响因子：
15.3
作者：
Bhatt, Jaimin R.;Finelli, Antonio
通讯作者：
Finelli, Antonio
DOI：
10.1152/ajprenal.90286.2008
发表时间：
2008-09-01
影响因子：
4.2
作者：
Addla, Sanjai K.;Brown, Mick D.;Clarke, Noel W.
通讯作者：
Clarke, Noel W.